Episode
Bolus or drip? What the DOSE trial actually showed about heart failure
- Podcast
- The Podcast by KevinMD
- Published
- May 11, 2026
- Duration seconds
- 1296
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-podcast-by-kevinmd-449609/episodes/bolus-or-drip-what-the-dose-trial-actually-showed-about-heart-failure/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-podcast-by-kevinmd-449609/bolus-or-drip-what-the-dose-trial-actually-showed-about-heart-failure.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What if one of the most common escalation strategies for acute heart failure doesn't actually improve outcomes? Internal medicine physicians Benjamin P. Geisler, Jeffrey L. Greenwald, and Kathy May Tran, editors of 50 Studies Every Hospitalist Should Know, join the show to break down what the DOSE trial really tells us about managing diuretics on the wards. Based on their KevinMD article " Managing acute heart failure: evidence from the DOSE trial ," they explain why continuous furosemide infusions showed no clinical advantage over intermittent boluses for decongestion, and what that means for your daily practice. You will hear how headline-driven medicine can mislead clinicians, why knowing who was excluded from a trial matters as much as the results, and how evidence-based medicine teaching is evolving in the age of AI. Whether you are a hospitalist, a trainee on the wards, or a primary care physician managing heart failure transitions, this episode will sharpen how you read and apply the studies that shape patient care. Tune into our episode " 2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring ," brought to you by Novartis Pharmaceuticals Corporation. For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol . VISIT SPONSOR → ht…